Scancell Holdings Plc · LSE:SCLP
Scancell — FY2024 Earnings Presentation
20 slides from Scancell's earnings presentation, Sep 24, 2024
Slide 1: Advancing Cancer Immunotherapy
DEVELOPING ANTIBODIES AND VACCINES FOR CANCER Advancing Cancer Immunotherapy Business Update and Results for Year Ending 30th April 2024 Lindy Durrant, CEO Sath Nirmalananthan, CFO 24 September 2024 LSE: SCLP.L
Slide 2: Disclaimer
Disclaimer For the purposes of this disclaimer, this “presentation” shall mean and include the slides that follow, the oral presentation of the slides by Scancell Holdings plc (the “Company”) or any person on its behalf, any question-and-answer session that follows the oral presentation, hard copies
Slide 3: Key Highlights
Key Highlights ► Positive efficacy signals from lead cancer vaccines with near-term clinical milestones ► SCIB1 with doublet CPI for unresectable melanoma exceeds 70% expectation with reported results in 13 patients ► SCOPE study recruitment at 36 for SCIB1 and 27 for iSCIB1+ ► Modi-1 safe as a mono
Slide 4: Pipeline: Multiple Value Drivers with Therapeutic Potential
Pipeline: Multiple Value Drivers with Therapeutic Potential Near-term focus on Scope & ModiFY study Indication Preclinical Phase 1 Phase 2 Phase 3 Clinical Data SCIB1 / iSCIB1+ Unresectable Melanoma Q4 2024/ H1 2025 (SCOPE Study) Renal cell carcinoma, Modi-1 Head & Neck, Ovarian, H1 2025 (ModiFY Stu
Slide 5: Immunobody DNA Vaccine Platform
Immunobody® DNA Vaccine Platform Unlocking potential for non-personalised cancer vaccines APC NEEDLE TARGETED OFF THE SHELF LOW TOXICITY CUSTOMISABLE FREE VACCINE Targets antigen Robust GMP manufacturing Delivers a spring-powered Favourable safety profile DNA targets can be adapted presenting cells
Slide 6: Scancell Signs Strategic Partnership with PharmaJet
Scancell Signs Strategic Partnership with PharmaJet Stratis® Intramuscular Needle-free delivery System for development of SCIB1/iSCIB1+ ► Stratis® has shown effective uptake of the DNA vaccine ► Widely accepted and favored by patients and clinicians throughout the SCOPE Study ► Stratis® has U.S. FDA
Slide 7: SCIB1/iSCIB1+ are Dual Action Tumour Targeted DNA Cancer Vaccines
SCIB1/iSCIB1+ are Dual Action Tumour Targeted DNA Cancer Vaccines with a Favorable Safety Profile TUMOUR TARGETED Incorporates specific epitopes from gp100 and TRP-2 proteins identified from T cells of patients who achieved spontaneous recovery from melanoma skin cancers DUAL ACTION Direct and indir
Slide 8: Treatment landscape for unresectable melanoma
Treatment landscape for unresectable melanoma SCIB1/ iSCIB1+ is used alongside double checkpoint inhibitor nivolumab and ipilimumab Unresectable Melanoma ► Phase II SCOPE trial, SCIB1/ iSCIB1+ is used alongside BRAF+ BRAF- double checkpoint inhibitor nivolumab and ipilimumab as a treatment for unres
Slide 9: SCOPE Study Design
SCOPE Study Design ENDPOINTS Eligibility Cohorts Endpoints Histologically confirmed unresectable Three cohorts across 16 sites in the UK: Primary Endpoints AJCC stage III or stage IV melanoma Cohort 1: SCIB1 + SoC nivolumab and ORR No prior treatment for advanced disease ipilimumab (n=36) Se
Slide 10: SCOPE Study Participating Sites
SCOPE Study Participating Sites Participating Sites Principal Investigator 01 Nottingham City Hospital Professor Poulam Patel 02 Velindre Cancer Centre, Cardiff Dr Satish Kumar 03 Mount Vernon Cancer Centre, Northwood Dr Heather Shaw 04 Churchill Hospital, Oxford Dr Miranda Payne 05 Royal Preston Ho
Slide 11: SCOPE Study: SCIB1 Simon Stage Results Cohort
SCOPE Study: SCIB1 Simon Stage 1 Results Cohort 1 SCOPE Study Cohort 1: Waterfall Plot Best Tumour Response SCOPE Response Kinetics: SCIB1 + Ipi-Nivo 80 (Target Lesions) 100.0 % Change in target lesion(s) from baseline 60 80.0 67.7 % Change in Target lesion(s) from Baseline 40 60.0 1 12 40.0 20 11 9
Slide 12: SCOPE Patients Demonstrate Potent Vaccine Specific T Cell Responses
SCOPE Patients Demonstrate Potent Vaccine Specific T Cell Responses p= <0.0001 4500 4000 3500 3000 Cohort 1 patients 2500 Nomalised spot count per million cultured PBMCs 2000 1500 ► Best T cell response for any peptide at any 1000 time point post vaccination plotted against 500 corresponding respons
Slide 13: ModiFY Study Progress Update
ModiFY Study Progress Update ENDPOINTS Dose escalation and Safety Dose expansion Endpoints Primary Endpoints Monotherapy tested across 4 tumour types Monotherapy across 4 tumour types ORR Low and high dose tested as monotherapy Combination therapy in two tumour types Secondary Endpoints
Slide 14: Portfolio of Patent Protected Anti-Glycan Antibodies
Portfolio of Patent Protected Anti-Glycan Antibodies with Therapeutic Development Potential Targeting highly specific and highly differentiated Deliver differentiated products for glycans preferentially expressed on tumours unmet markets • Genmab licensed for ADC/TCB/radioimmunotherapy SC129 • Sialy
Slide 15: Opportunity for SC134 in SCLC
Opportunity for SC134 in SCLC Small Cell Lung Cancer • Currently very few 1L treatment options for SCLC patients • 250,000 patient population • 75% diagnosed with aggressive form of the disease • Clinically validated target (BMS-986012)due to start Phase 3 study • Poor prognosis with 5-year survival
Slide 16: Timelines and Outlook
Timelines and Outlook 16
Slide 17: Scancell Key Financial Highlights
Scancell Key Financial Highlights Consolidated Statement of 12 months 12 months Comprehensive Income (£m) 30 April 2024 30 April 2023 ► Revenue in FY23 relates to SC129 upfront. Further revenue opportunities as with Revenue - 5.3m SC129 development on track & antibodies under evaluation. Gross Profi
Slide 18: Strong pipeline of news flow
Strong pipeline of news flow 2024 2025 2026+ SCIB1 & doublet CPI iSCIB1+ doublet CPI SCIB1/ 27/43 responses 27/43 responses Results of iSCIB1+ Phase 2 randomised trial1 SCOPE VACCINES iSCIB1+ doublet CPI initiation Start Phase 2/3 registration study1 Modi-1 Modi-1 CPI expansion Early clinical result
Slide 19: Outlook
Outlook Near term clinical milestones and value drivers SCOPE Study • Full cohort data with SCIB1 and iSCIB1+ in Q4 2024 and H1 2025 • Phase 2/3 seamless registration trial with SCIB1 or iSCIB1+ to begin in 2025 ModiFY • ModiFY study data in RCC in combination with checkpoint inhibitors expected in
Slide 20: Thank you
Thank you www.scancell.co.uk 20